▼

Sunday, July 3, 2011

‘Triple-Negative’ Breast Cancer Study May Help Guide Treatment Plan (06/30/11)


6/30/2011 - Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called “triple-negative breast cancer (TNBC).”


Not Just 1 disease but 6 subtypes of Triple Negative Breast Cancer and  identifying the different chemotherapies that they respond to:
  • BL1 and BL2 - These 2 "basal-like" types relates to cell cycle and DNA response genes and responds to the drug, Cisplatin.
  • M and MSL - These two "mesenchymal" types are driven by genes as it relates to cell differentiation and growth factor pathways that responds to the drug, Dasatinib and an experimental drug, NVP-BEZ235.
  • IM - A "immunomodulatory" type as it relates to immune system genes.
  • LAR - A "luminal" type relates to the "male" sex hormone, androgen signals and responds to the drug, Bicalutamide.
(Click to link)